March 19, 2013 at 09:35 AM EDT
UPDATE: Cantor Fitzgerald Lowers PT on Ventrus Biosciences on 4Q Earnings Report
Cantor Fitzgerald analyst Adeyemi Ogunkoya published a report on Ventrus Biosciences (NASDAQ: VTUS ) that maintained its Buy rating and lowered the price target from $6 to $5. Cantor Fitzgerald reported that, “The lower-than-expected spending was associated with the closure of the VEN-309 hemorrhoid program. We have updated our 2013
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here